CELLDEX THERAPEUTICS INC NEW's ticker is CLDX and the CUSIP is 15117B202. A total of 162 filers reported holding CELLDEX THERAPEUTICS INC NEW in Q3 2021. The put-call ratio across all filers is 0.67 and the average weighting 0.4%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $3,366,824 | -18.9% | 122,341 | -0.0% | 2.26% | -19.8% |
Q2 2023 | $4,151,098 | -5.0% | 122,343 | +0.7% | 2.81% | -12.7% |
Q1 2023 | $4,371,570 | -14.7% | 121,500 | +5.7% | 3.22% | +2.1% |
Q4 2022 | $5,125,550 | -31.8% | 115,000 | -57.0% | 3.15% | -2.5% |
Q3 2022 | $7,511,000 | +4.3% | 267,195 | 0.0% | 3.23% | -19.4% |
Q2 2022 | $7,204,000 | -34.5% | 267,195 | -17.3% | 4.01% | -21.9% |
Q1 2022 | $10,998,000 | -16.3% | 322,898 | -5.1% | 5.14% | -7.0% |
Q4 2021 | $13,141,000 | -27.9% | 340,098 | +0.8% | 5.52% | -14.1% |
Q3 2021 | $18,222,000 | -63.4% | 337,500 | -77.3% | 6.43% | -67.7% |
Q2 2021 | $49,739,000 | +137.3% | 1,487,406 | +46.2% | 19.88% | +163.0% |
Q1 2021 | $20,961,000 | -26.5% | 1,017,524 | -37.5% | 7.56% | -2.6% |
Q4 2020 | $28,514,000 | +24.5% | 1,627,500 | +5.3% | 7.76% | +24.7% |
Q3 2020 | $22,912,000 | +76.2% | 1,545,000 | +54.5% | 6.22% | +65.7% |
Q2 2020 | $13,000,000 | – | 1,000,000 | – | 3.76% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Kynam Capital Management, LP | 1,605,390 | $71,552,232 | 10.98% |
Octagon Capital Advisors LP | 761,398 | $33,935,509 | 5.28% |
TSP Capital Management Group, LLC | 269,895 | $12,029,225 | 4.50% |
Redmile Group, LLC | 1,977,451 | $88,134,991 | 3.60% |
COMMODORE CAPITAL LP | 495,823 | $22,099 | 3.33% |
Tri Locum Partners LP | 176,109 | $7,849,000 | 3.18% |
ACUTA CAPITAL PARTNERS, LLC | 115,000 | $5,125,550 | 3.15% |
Ikarian Capital, LLC | 267,476 | $11,921,406 | 2.88% |
RTW INVESTMENTS, LP | 3,084,215 | $137,463,463 | 2.81% |
Eversept Partners, LP | 558,774 | $24,904,557 | 2.18% |